Spoken Alpha
IONIS PHARMACEUTICALS INC
Ionis Pharmaceuticals designs RNA-targeted medicines to treat serious diseases. The company markets seven approved medicines for conditions including spinal muscular atrophy, amyotrophic lateral sclerosis, hereditary angioedema, and rare metabolic and neurological disorders, with revenue of $944 million in 2025.
IONIS PHARMACEUTICALS INC is a Healthcare company operating in Biotechnology with a $9.01B market cap.
Most recent reported earnings: Q3 FY2026 (Nov 3, 2026).
22 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Disclosures
Extracted from SEC 10-K filing, 2026-08-30.
Transcripts
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
History
Executives who appear on this company's earnings calls in our corpus, with role and tenure sourced from SEC filings. Click any name for the full role timeline and call appearance history. Per-executive behavioral deviation metrics are available to research subscribers.
Peers
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for IONS.
$ curl https://api.spokenalpha.com/v1/companies/IONSFAQ
Spoken Alpha indexes IONS's earnings call transcripts at https://spokenalpha.com/companies/IONS. Each call links to attributed speakers and parsed analyst Q&A. IONIS PHARMACEUTICALS INC's own investor relations page is at https://ir.ionis.com/.
IONIS PHARMACEUTICALS INC (IONS) held its most recent earnings call on 2026-07-29, covering fiscal Q2 2026.
IONIS PHARMACEUTICALS INC (IONS) operates in the Healthcare sector (Biotechnology industry).
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q3 FY2026 | 2026-11-03 | — | $-1.21 | — | — | — | — | EODHD |
| Q2 FY2026 | 2026-07-28 | $-0.70 | $-1.09 | +35.8% | $267.9M | — | — | EODHD |
| Q1 FY2026 | 2026-04-28 | $-0.30 | $-0.77 | +61.0% | $246.1M | — | — | EODHD |
| Q4 FY2025 | 2026-02-24 | $-1.15 | $-1.33 | +13.7% | $203.0M | — | — | EODHD |
| Q3 FY2025 | 2025-10-28 | $-0.61 | $-1.05 | +41.9% | $156.7M | — | — | EODHD |
| Q2 FY2025 | 2025-07-29 | $0.85 | $0.16 | +100.0% | $452.0M | — | — | EODHD |
| Q1 FY2025 | 2025-04-29 | $-0.92 | $-1.03 | +10.7% | $131.6M | — | — | EODHD |
| Q4 FY2024 | 2025-02-18 | $-0.43 | $-0.84 | +49.0% | $226.6M | — | — | EODHD |
| Q3 FY2024 | 2024-11-05 | $-0.95 | $-1.16 | +18.1% | $133.8M | — | — | EODHD |
| Q2 FY2024 | 2024-07-31 | $-0.24 | $-0.76 | +68.4% | $225.3M | — | — | EODHD |
| Q1 FY2024 | 2024-05-06 | $-0.77 | $-0.83 | +7.2% | $119.5M | — | — | EODHD |
| Q4 FY2023 | 2024-02-20 | $-0.06 | $-0.83 | +92.8% | $119.5M | — | — | EODHD |
| Q3 FY2023 | 2023-11-01 | $-0.85 | $-0.89 | +4.5% | $144.2M | — | — | EODHD |
| Q2 FY2023 | 2023-08-08 | $-0.41 | $-0.70 | +41.4% | $188.4M | — | — | EODHD |
| Q1 FY2023 | 2023-05-02 | $-0.68 | $-0.76 | +10.5% | $130.5M | — | — | EODHD |
| Q4 FY2022 | 2023-02-21 | $-1.36 | $-0.92 | -47.8% | $151.9M | — | — | EODHD |
| Q3 FY2022 | 2022-11-08 | $-0.16 | $-0.53 | +69.8% | $159.8M | — | — | EODHD |
| Q2 FY2022 | 2022-08-08 | $-0.56 | $-0.47 | -19.1% | $133.8M | — | — | EODHD |
| Q1 FY2022 | 2022-05-03 | $-0.27 | $-0.52 | +48.1% | $141.9M | — | — | EODHD |
| Q4 FY2021 | 2022-02-23 | $1.41 | $0.28 | +100.0% | $440.0M | — | — | EODHD |
Source: EODHD. IONS reported actuals as published; sparse fields render as —.